Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy.
about
Cardiac remodelling: concentric versus eccentric hypertrophy in strength and endurance athletesRationale and design of the SMART Heart study: A prediction model for left ventricular hypertrophy in hypertensionEchocardiography-based left ventricular mass estimation. How should we define hypertrophy?The case for inhibiting p38 mitogen-activated protein kinase in heart failureIs the 'athlete's heart' arrhythmogenic? Implications for sudden cardiac deathThe role of echocardiography in the differential diagnosis between training induced myocardial hypertrophy versus cardiomyopathyPICOT is a critical regulator of cardiac hypertrophy and cardiomyocyte contractilityGender and post-ischemic recovery of hypertrophied rat heartsNon-coding RNAs in cardiac hypertrophy.Inhibition of Let-7 microRNA attenuates myocardial remodeling and improves cardiac function postinfarction in mice.Rac-induced left ventricular dilation in thyroxin-treated ZmRacD transgenic mice: role of cardiomyocyte apoptosis and myocardial fibrosis.Sizing up models of heart failure: Proteomics from flies to humans.Diabetes, gender, and left ventricular structure in African-Americans: the atherosclerosis risk in communities study.Carbamazepine alone and in combination with doxycycline attenuates isoproterenol-induced cardiac hypertrophy.Left ventricular hypertrophy in hypertension: its arrhythmogenic potential.Functions of autophagy in pathological cardiac hypertrophyThe role of cardiovascular magnetic resonance in the evaluation of patients with heart failure.Re-employment of developmental transcription factors in adult heart diseaseInternational Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].MAP kinase kinase kinase-2 (MEKK2) regulates hypertrophic remodeling of the right ventricle in hypoxia-induced pulmonary hypertension.Asymptomatic obese hypertensives and need of routine echocardiography for left ventricular mass assessment and treatment.Effect of hepatocyte growth factor and angiotensin II on rat cardiomyocyte hypertrophy.Cardiomyocyte proliferation in zebrafish and mammals: lessons for human disease.AMPK in Cardiovascular Diseases.Rapamycin Inhibits Cardiac Hypertrophy by Promoting Autophagy via the MEK/ERK/Beclin-1 Pathway.Function and expression of ATIP and its variants in cardiomyoblast cell line H9c2.Phosphorylation of the chromatin remodeling factor DPF3a induces cardiac hypertrophy through releasing HEY repressors from DNAFluorescence lifetime of actin in the familial hypertrophic cardiomyopathy transgenic heart.Transcriptome of hypertension-induced left ventricular hypertrophy and its regression by antihypertensive therapies.Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarctionReversal of isoprenaline-induced cardiac remodeling by rutaecarpine via stimulation of calcitonin gene-related peptide production.Exercise training inhibits inflammatory cytokines and more than prevents myocardial dysfunction in rats with sustained beta-adrenergic hyperactivity.MEF2 transcriptional activity maintains mitochondrial adaptation in cardiac pressure overload.A prediction model for left ventricular mass in patients at high cardiovascular risk.A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy.Relief from a heavy heart: redox-sensitive NF-kappaB as a therapeutic target in managing cardiac hypertrophy.Paracrine Effects of the Pluripotent Stem Cell-Derived Cardiac Myocytes Salvage the Injured Myocardium.Early detection of cardiac alterations by left atrial strain in patients with risk for cardiac abnormalities with preserved left ventricular systolic and diastolic function.RV pressure overload: from hypertrophy to failure.Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy
P2860
Q24653777-AA8A273D-F52A-472C-B568-B90F8EF92E6DQ24680384-CD5FBCDC-26B1-44E4-97E3-5375671FA665Q24810969-7768E733-1225-4354-BF38-8A534DC5675AQ28080674-BD510F1D-2B9E-45C7-A23C-54984F1C58DBQ28236101-530B2450-3C37-4A41-8BB1-F1E766FF47AAQ30448280-79FC43F0-35BC-4AA3-9740-D4CE52A4711BQ30490584-96EE200B-8CE3-42AD-B9E9-9930C6726424Q30810165-359D6876-9B7F-4DBD-A0E5-B7321B02A344Q33800147-0F503609-16EA-42B5-A47C-5CE9685F1F9CQ34292584-BBA7BFB5-2B86-4491-B2BA-2820379C0B3EQ34398861-486D8A48-787B-45C1-8BA2-0544595D8C91Q34808730-44EC13AF-2471-4BAB-BBDB-BE645080D451Q35157562-23B74F7F-BF57-4105-B992-45A798B5EC73Q35252841-E90C0FF9-5E0C-4445-8484-41524299210EQ35583519-B6E04E98-0D62-4D9C-8CB3-CAA73EBF3490Q35632729-F0DFC485-1C44-4349-88E2-A026E22B22C8Q35706849-8490060A-DA88-4B34-A4EC-CDBF1A15FA24Q35757916-5E36EDCB-E9F1-4D8E-8C1E-673ABA68DC4AQ36241932-AF572ED2-531F-46B0-877C-56C491C360CFQ36528033-E25C8CF8-1AA8-445F-B228-7A26288B7D66Q37197090-88765CF0-00A0-44A1-BD07-71A26CEB2859Q37370965-C354C1FE-B348-420D-B5E2-0DEB6F86A0D0Q38998289-E42C9844-B4A2-4220-A23E-BD1CF2F0CF0EQ38998410-CEE4865C-4992-45DC-B9E6-4B0A585B3FF5Q39104316-8A7D618E-8A7F-4138-BF2F-C1DA3540A49FQ39170846-F8613581-168C-457B-852F-EED502423830Q39949971-17CD8C25-A358-4447-884B-2087EE4D7683Q42551720-6AECA2AF-6731-4BA9-8178-9F27F5CB6811Q42616171-1B3A903A-660D-4C35-A45E-579CBEB9B6CFQ42758805-8A5E6C6D-207F-4ED6-9F5E-C39F66BAE37FQ42852264-413A3423-EBA8-4E8D-9D85-598D896DB19CQ43074266-8FB762C8-D2FC-47E0-8EC8-A6DDA59730DCQ43214524-73EE7BE3-D3C7-47FB-B647-6CF059CCD098Q44018957-043EC279-1D6B-479C-A2BE-CC2250E48B6AQ46211450-BC26E657-5EB1-48F5-8FF4-CE07843B46ACQ46551309-EA09A6A7-499E-49B8-952F-4389E4712AC1Q48028186-7AA852BF-518F-4FCD-BDC6-1D897CC30ABAQ48516385-306B1FC8-C55A-4B46-AC47-C02739CE9409Q49679389-7FD231DE-7099-44FB-9CA7-4760025078F6Q58728912-B1AA3094-8924-415A-B04A-28A16668A830
P2860
Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Molecular determinants of myoc ...... l and maladaptive hypertrophy.
@ast
Molecular determinants of myoc ...... l and maladaptive hypertrophy.
@en
type
label
Molecular determinants of myoc ...... l and maladaptive hypertrophy.
@ast
Molecular determinants of myoc ...... l and maladaptive hypertrophy.
@en
prefLabel
Molecular determinants of myoc ...... l and maladaptive hypertrophy.
@ast
Molecular determinants of myoc ...... l and maladaptive hypertrophy.
@en
P2093
P1476
Molecular determinants of myoc ...... l and maladaptive hypertrophy.
@en
P2093
Daniel J Lips
Dave J W van Kraaij
Leon J deWindt
Pieter A Doevendans
P304
P356
10.1016/S0195-668X(02)00829-1
P577
2003-05-01T00:00:00Z